Download PDF
Onkologie up2date 2019; 1(01): 27-40
DOI: 10.1055/a-0809-8525
Tumoren der Atemwege
Georg Thieme Verlag KG Stuttgart · New York

Kleinzelliges Lungenkarzinom

Small Cell Lung Cancer
Niels Reinmuth
,
Hans Hoffmann
Further Information

Publication History

Publication Date:
06 February 2019 (online)

    Permissions and Reprints All articles of this category

Zusammenfassung

Das kleinzellige Lungenkarzinom stellt eine besonders aggressive Tumorentität dar und ist durch schnellen Progress, sehr frühe Metastasierung und schlechte Prognose charakterisiert. Nur wenige Patienten werden in einem frühen Erkrankungsstadium diagnostiziert, bei dem in ausgewählten Fällen eine chirurgische Resektion diskutiert werden kann. Chemotherapie und Strahlentherapie sind initial häufig effektiv. Allerdings erleiden die meisten Patienten im metastasierten Stadium nach zunächst gutem Ansprechen auf eine platinhaltige Chemotherapie einen Progress mit dann nur limitierten Therapieoptionen.

Abstract

Small cell lung cancer accounts for roughly 14% of all lung cancers and is characterized by rapid progression, early distant metastasis and poor prognosis. Only a minority of patients presents with early stage disease upon initial diagnosis where surgical resection may be discussed. In addition, various treatment modalities demonstrate effectiveness including chemotherapy and radiotherapy. However, although most patients respond to platinum doublet chemotherapy, virtually all patients with metastatic disease eventually develop tumor progression for which there are limited treatment options. Novel therapeutic approaches such as immune checkpoint inhibitors or the antibody drug conjugate rovalpituzumab tesirine show promising results in early clinical trials and might broaden our treatment options in the future.

Kernaussagen

  • Das kleinzellige Lungenkarzinom ist durch eine äußerst aggressive Verlaufsform, eine frühe Metastasierung und schlechte Prognose charakterisiert.

  • Alle Patienten sollten im Tumorboard interdisziplinär besprochen werden.

  • Im frühen Tumorstadium (N0, N1) sollte ein multimodales Therapiekonzept mit chirurgischer Resektion (Lobektomie und systematische Lymphadenektomie) angestrebt werden.

  • Bei kurativer Zielsetzung im Stadium III ist die Standardtherapie eine kombinierte Radiochemotherapie, die idealerweise simultan durchgeführt werden sollte.

  • Die Mehrzahl der Tumoren wird im bereits metastasierten Stadium diagnostiziert, bei denen eine (Kombinations-) Chemotherapie mit palliativer Intention die Standardtherapie darstellt.

  • Verschiedene neue Therapieansätze wie Checkpointinhibitoren und zielgerichtete Chemotherapie befinden sich in klinischer Testung.

Schlüsselwörter

Lungenkrebs - Bronchialkarzinom - Chemotherapie - Strahlentherapie - Tumorresektion - Immuntherapie

Key words

pulmonary cancer - bronchial carcinoma - chemotherapy - radiation therapy - tumor resection - immunotherapy
 

  • Literatur

  • 1 Robert Koch-Institut. Bericht zum Krebsgeschehen in Deutschland 2016. Berlin. Im Internet: https://www.krebsdaten.de/Krebs/DE/Content/Publikationen/Krebsgeschehen/Krebsgeschehen_node.html;jsessionid=4F042B8AAC409B0A51905B9FC903F3ED.1_cid381 Stand: 12.02.2018
    PubMedGoogle Scholar
  • 2 Nicholson AG, Chansky K, Crowley J. et al. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: proposals for the revision of the clinical and pathologic staging of small cell lung cancer in the forthcoming eighth edition of the TNM classification for lung cancer. J Thorac Oncol 2016; 11: 300-311
    CrossrefPubMedGoogle Scholar
  • 3 Goeckenjan G, Sitter H, Thomas M. et al. Prevention, diagnosis, therapy, and follow-up of lung cancer: interdisciplinary guideline of the German Respiratory Society and the German Cancer Society. Pneumologie 2010; 65: 39-59
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Takenaka T, Takenoyama M, Inamasu E. et al. Role of surgical resection for patients with limited disease-small celllung cancer. Lung Cancer 2015; 88: 52-56
    CrossrefPubMedGoogle Scholar
  • 5 Combs SE, Hancock JG, Boffa DJ. et al. Bolstering the Case for Lobectomy in Stages I, II, and IIIA Small-Cell Lung Cancer Using the National Cancer Data Base. J Thorac Oncol 2015; 10: 316-323
    CrossrefPubMedGoogle Scholar
  • 6 Wolf M, Eberhardt W, Martin Früh M. et al. http://www.onkopedia.com/de/onkopedia/guidelines/lungenkarzinom-kleinzellig-sclc/@@view/html/index.html Stand: 05.11.2017
    PubMed
  • 7 Yang CF J, Chan DY, Speicher PJ. et al. Surgery Versus Optimal Medical Management for N1 Small Cell Lung Cancer. Ann Thorac Surg 2017; 103: 1767-1772
    CrossrefPubMedGoogle Scholar
  • 8 Schreiber D, Rineer J, Weedon J. et al. Survival outcomes with the use of surgery in limited-stage small cell lung cancer: should its role be re-evaluated?. Cancer 2010; 116: 1350-1357
    CrossrefPubMedGoogle Scholar
  • 9 Wong AT, Rineer J, Schwartz D. et al. Assessing the impact of postoperative radiation therapy for completely resected limited-stage small cell lung cancer using the National Cancer Database. J Thorac Oncol 2016; 11: 242-248
    CrossrefPubMedGoogle Scholar
  • 10 Aupérin A, Arriagada R, Pignon JP. et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 1999; 341: 476-484
    CrossrefPubMedGoogle Scholar
  • 11 Souhami RL, Law K. Longevity in small cell lung cancer. A report to the Lung Cancer Subcommittee of the United Kingdom Coordinating Committee for Cancer Research. Br J Cancer 1990; 61: 584-589
    CrossrefPubMedGoogle Scholar
  • 12 Schmittel A, Sebastian M, Fischer von Weikersthal L. et al. A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer. Ann Oncol 2011; 22: 1798-1804
    CrossrefPubMedGoogle Scholar
  • 13 OʼBrien ME, Ciuleanu TE, Tsekov H. et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 2006; 24: 5441-5447
    CrossrefPubMedGoogle Scholar
  • 14 von Pawel J, Jotte R, Spigel DR. et al. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. J Clin Oncol 2014; 32: 4012-4019
    CrossrefPubMedGoogle Scholar
  • 15 Inomata M, Hayashi R, Tokui K. et al. Outcome and prognostic factors in patients with small cell lung cancer who receive third-line chemotherapy. Tumori 2014; 100: 507-511
    CrossrefPubMedGoogle Scholar
  • 16 Slotman B, Faivre-Finn C, Kramer G. et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 2007; 357: 664-672
    CrossrefPubMedGoogle Scholar
  • 17 Takahashi T, Yamanaka T, Seto T. et al. Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2017; 18: 663-671
    CrossrefPubMedGoogle Scholar
  • 18 Slotman BJ, van Tinteren H, Praag JO. et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lancet 2014; 385: 36-42
    PubMedGoogle Scholar
  • 19 Yu H, Batenchuk C, Badzio A. et al. PD-L1 Expression by two complementary diagnostic assays and mRNA in situ hybridization in small cell lung cancer. J Thorac Oncol 2016; 12: 110-120
    PubMedGoogle Scholar
  • 20 Reck M, Luft A, Szczesna A. et al. Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer. J Clin Oncol 2016; 34: 3740-3748
    CrossrefPubMedGoogle Scholar
  • 21 Ott PA, Elez E, Hiret S. et al. Pembrolizumab in patients with extensive-stage small-cell lung cancer: results from the phase Ib KEYNOTE-028 Study. J Clin Oncol 2017; 35: 3823-3829
    CrossrefPubMedGoogle Scholar
  • 22 Hellmann MD, Ott PA, Zugazagoitia J. et al. Nivolumab (nivo) ± ipilimumab (ipi) in advanced small-cell lung cancer (SCLC): First report of a randomized expansion cohort from CheckMate 032. J Clin Oncol 2017; 35: abstr 8503
    CrossrefGoogle Scholar
  • 23 Rudin CM, Pietanza MC, Bauer TM. et al. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. Lancet Oncol 2016; 18: 42-51
    PubMedGoogle Scholar